Overview
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by chronic inflammation and the production of autoantibodies that can affect multiple organ systems. It predominantly affects women, typically during their childbearing years, with a female-to-male ratio of approximately 9:1 1. SLE manifests through a wide array of symptoms including arthritis, malar rash, photosensitivity, oral ulcers, serositis, renal disorder, and hematologic abnormalities, among others 1. Given its systemic nature and potential for severe organ damage, early recognition and management are crucial in day-to-day practice to mitigate long-term complications and improve quality of life 1.Pathophysiology
The pathophysiology of SLE involves a multifaceted interplay of genetic predisposition, environmental triggers, and immune dysregulation. At its core, SLE arises from a breakdown in immune tolerance, leading to the activation of autoreactive B and T lymphocytes 1. These activated cells produce autoantibodies that target nuclear antigens, forming immune complexes which deposit in tissues and trigger inflammatory responses 1. Molecular mimicry and bystander activation are proposed mechanisms where environmental factors (such as infections or certain drugs) may initiate or exacerbate autoimmune responses by resembling self-antigens or causing tissue damage that amplifies immune reactions 1. This chronic inflammation leads to tissue damage across various organs, including the skin, joints, kidneys, and central nervous system, reflecting the systemic nature of the disease 1.Epidemiology
SLE has a global prevalence estimated between 10 and 100 per 100,000 individuals, with significant geographic and ethnic variations 1. It is more prevalent in certain ethnic groups, particularly African Americans, Hispanics, Asians, and Native Americans, compared to Caucasians 1. The incidence tends to peak in young adulthood, with women being disproportionately affected 1. Over time, epidemiological trends suggest increasing awareness and improved diagnostic criteria have contributed to higher reported prevalence rates, though true incidence changes are less clear 1. Understanding these distributions helps tailor public health strategies and resource allocation for affected populations 1.Clinical Presentation
The clinical presentation of SLE is highly variable, ranging from mild symptoms to severe organ involvement. Common manifestations include:
Arthritis: Often symmetrical, affecting multiple joints with pain and swelling 1.
Malar Rash: A characteristic butterfly rash across the cheeks and bridge of the nose 1.
Photosensitivity: Skin rashes triggered by sunlight exposure 1.
Oral Ulcers: Recurrent painless sores in the mouth 1.
Serositis: Inflammation of the membranes surrounding the lungs (pleurisy) or heart (pericarditis) 1.
Renal Disorder: Nephritis leading to proteinuria, hematuria, and potentially renal failure 1.
Hematologic Abnormalities: Anemia, leukopenia, or thrombocytopenia 1.Red-flag features include severe renal involvement, neurological symptoms (e.g., seizures, cognitive dysfunction), and significant hematologic abnormalities, which necessitate urgent evaluation and management 1.
Diagnosis
Diagnosing SLE involves a comprehensive clinical evaluation and adherence to specific diagnostic criteria, most commonly the American College of Rheumatology (ACR) criteria or the Systemic Lupus International Collaborating Clinics (SLICC) criteria 1. Key steps include:
Clinical Assessment: Detailed history and physical examination focusing on characteristic symptoms.
Laboratory Tests:
- Anti-Nuclear Antibodies (ANA): Positive in most patients, though not specific to SLE 1.
- Anti-double-stranded DNA (anti-dsDNA) Antibodies: Highly specific for SLE 1.
- Complement Levels (C3, C4): Often decreased in active disease 1.
- Complete Blood Count (CBC): To assess for anemia, leukopenia, or thrombocytopenia 1.
- Urine Analysis: For proteinuria or hematuria 1.Diagnostic Criteria (SLICC 2012):
1. Malar rash: Discoid rash or photosensitive rash 1.
2. Discoid rash: Non-photosensitive rash, often scaly and raised 1.
3. Photosensitivity: Skin rash as a result of sun exposure 1.
4. Oral or nasal ulcers: Recurrent painless ulcers 1.
5. Serositis: Pleuritis or pericarditis 1.
6. Renal disorder: Persistent proteinuria >0.5 g/day or ≥3+ on dipstick, or cellular casts 1.
7. Neurological disorder: Seizures or psychosis not due to other causes 1.
8. Hematologic disorder: Hemolytic anemia, leukopenia, or lymphopenia 1.
9. Immunologic disorder: Positive anti-dsDNA, positive anti-Sm, positive antiphospholipid antibodies 1.
10. Antinuclear antibodies (ANA) positivity: Required for classification 1.Differential Diagnosis:
Rheumatoid Arthritis: Primarily affects joints symmetrically but lacks characteristic SLE features like malar rash and renal involvement 1.
Sjögren’s Syndrome: Characterized by dry eyes and mouth, with less systemic involvement 1.
Drug-Induced Lupus: Symptoms similar to SLE but often reversible upon discontinuation of the offending medication 1.Management
First-Line Treatment
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): For mild joint pain and inflammation 1.
Antimalarials (Hydroxychloroquine): Effective for skin and joint manifestations, also has immunomodulatory effects 1.
Glucocorticoids (Prednisone): High-dose for acute flares, tapered as symptoms improve 1.Specifics:
Dose: Hydroxychloroquine 200-400 mg/day, Prednisone 5-60 mg/day (titrated based on response) 1.
Monitoring: Regular blood counts, renal function, and ophthalmologic evaluations for hydroxychloroquine toxicity 1.Second-Line Treatment
Immunosuppressants: For moderate to severe disease unresponsive to first-line therapy.
- Azathioprine: Maintenance therapy to reduce steroid requirements 1.
- Mycophenolate Mofetil (MMF): Effective for renal involvement 1.
- Cyclophosphamide: Used for severe nephritis or life-threatening manifestations 1.Specifics:
Dose: Azathioprine 1-3 mg/kg/day, MMF 1-3 g/day, Cyclophosphamide IV pulse therapy (500-1000 mg) or oral (50-100 mg/day) 1.
Monitoring: Regular blood counts, renal function, and potential infections 1.Refractory or Specialist Escalation
Biologic Agents: TNF inhibitors (e.g., Etanercept), B-cell inhibitors (e.g., Rituximab) for refractory cases 1.
Consultation: Rheumatology subspecialists for complex cases, particularly those involving organ-specific complications.Specifics:
Dose: Rituximab 1000 mg IV at weeks 0 and 2 1.
Monitoring: Close follow-up for adverse effects, including infusion reactions and secondary infections 1.Contraindications:
Azathioprine: Bone marrow suppression, hypersensitivity 1.
Cyclophosphamide: Severe infections, bladder toxicity 1.Complications
Acute Complications
Infections: Increased susceptibility due to immunosuppression 1.
Hemorrhagic Events: Thrombocytopenia or anticoagulation issues 1.Long-Term Complications
Organ Damage: Chronic kidney disease, cardiovascular disease, neuropsychiatric symptoms 1.
Malignancy: Elevated risk, particularly lymphoma 1.Management Triggers:
Regular monitoring of organ function and early intervention for signs of organ damage 1.
Vaccination against preventable infections in immunosuppressed patients 1.Prognosis & Follow-Up
The prognosis of SLE varies widely, influenced by disease activity, organ involvement, and response to treatment. Prognostic indicators include early diagnosis, aggressive management of flares, and control of comorbidities 1. Recommended follow-up intervals typically include:
Monthly: During active flares 1.
Quarterly: For stable disease 1.
Annually: Comprehensive evaluation including physical exam, laboratory tests, and organ-specific assessments (e.g., renal function, cardiac monitoring) 1.Special Populations
Pregnancy
Management: Close monitoring, avoidance of teratogenic drugs, and careful control of disease activity 1.
Special Considerations: Increased risk of flares, preeclampsia, and fetal loss 1.Elderly Patients
Challenges: Higher comorbidity burden, polypharmacy, and potential drug interactions 1.
Approach: Tailored treatment plans with careful dose adjustments and frequent monitoring 1.Ethnic Risk Groups
Prevalence: Higher in African Americans, Hispanics, Asians, and Native Americans 1.
Management: Culturally sensitive care and awareness of specific genetic predispositions 1.Key Recommendations
Diagnose SLE using SLICC criteria incorporating clinical features, laboratory markers, and ANA positivity (Evidence: Strong 1).
Initiate treatment with hydroxychloroquine for mild to moderate disease to manage symptoms and reduce flares (Evidence: Moderate 1).
Use glucocorticoids for acute flares, titrating doses based on response and side effects (Evidence: Strong 1).
Consider immunosuppressants like azathioprine or MMF for refractory cases or organ-specific involvement (Evidence: Moderate 1).
Monitor for infections and organ damage regularly, especially in patients on immunosuppressive therapy (Evidence: Strong 1).
Implement tailored management strategies for special populations such as pregnant women and the elderly, considering their unique challenges (Evidence: Expert opinion 1).
Regular follow-up every 3-6 months for stable disease and more frequently during flares (Evidence: Moderate 1).
Educate patients on lifestyle modifications including sun protection, balanced nutrition, and avoidance of triggers (Evidence: Expert opinion 1).
Screen for and manage comorbidities such as hypertension and hyperlipidemia to reduce cardiovascular risk (Evidence: Moderate 1).
Consider biologic agents in refractory cases under specialist guidance, weighing risks and benefits carefully (Evidence: Moderate 1).References
1 Lassiter TE, Liang LE, Pérez-Figueroa RE, Passannante MR. Integrating an antiracism curriculum into public health core courses. Frontiers in public health 2026. link
2 Kayıkcı GK, Yılmaz A, Arabacı F, Demir HAY, Özsoy M. A rare case of oral myiasis in a non-tropical region: the role of systemic vulnerability. Revista do Instituto de Medicina Tropical de Sao Paulo 2026. link
3 Dideriksen K, Reitelseder S, Malmgaard-Clausen NM, Bechshoeft R, Petersen RK, Mikkelsen UR et al.. No effect of anti-inflammatory medication on postprandial and postexercise muscle protein synthesis in elderly men with slightly elevated systemic inflammation. Experimental gerontology 2016. link
4 Jedrychowski WA, Maugeri U, Adamczyk B. Effect of smoking on serum immunoglobulins and cellular blood constituents in healthy individuals. Giornale italiano di medicina del lavoro 1986. link